Access cutting-edge hepatocellular carcinoma treatment through this clinical trial at a research site in Buffalo. Study-provided care at no cost to qualified participants.
Access hepatocellular carcinoma specialists in Buffalo at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hepatocellular carcinoma treatment provided free
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab in the second line setting for locally advanced unresectable, recurrent, and/or metastatic HCC cohort and to assess the efficacy and safety of RP2 in combination with durvalumab after chemotherapy is discontinued in the first line setting for unresectable locally advanced or metastatic BTC cohort.
Sponsor: Replimune Inc.
Check if you qualify for this hepatocellular carcinoma clinical trial in Buffalo, NY
If you're searching for hepatocellular carcinoma treatment options in Buffalo, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Buffalo research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hepatocellular carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.